ALK and ROS1 Double-Rearranged Lung Squamous Cell Carcinoma Responding to Crizotinib Treatment: A Case Report-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

ALK and ROS1 Double-Rearranged Lung Squamous Cell Carcinoma Responding to Crizotinib Treatment: A Case Report

Published:2017-12 Issue:12 Volume:12 Page:e193-e197
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Li Qiong,Wu Jian,Yan Li-Xu,Huang Jun-Wei,Zhang Zhou,Zhang Jin-E,Gao Xing-Lin,Luo Ze-Ru,Liu Jing,Yang Shi-Fang,Liu Yan-Hui

Funder

Health Care Collaborative Innovation Major Projects of Guangzhou

Science and Technology Program of Guangdong

Guangdong Medical Science and Technology Research Foundation

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference6 articles.

1. National Working Group Meeting on ALK diagnostics in lung cancer;Cooper;Asia Pac J Clin Oncol,2014

2. Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations;Chen;J Thorac Oncol,2014

3. First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer;Mikes;Lung Cancer,2015

4. Clinical relevance of ROS1 rearrangements detection in advanced squamous cell carcinomas;Gibelin;Lung Cancer,2016

5. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage;Newman;Nat Med,2014

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project;Lung Cancer;2024-08

2. Efficacy analysis of ALK inhibitors for treating lung squamous carcinoma patients harboring ALK rearrangement;Journal of Thoracic Disease;2024-07

3. Ros1 Fusions in Resected Stage I-Iii Adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape Project;2024

4. Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients;Genes & Genomics;2022-11-29

5. Coexpression of ΔNp63/p40 and TTF1 Within Most of the Same Individual Cells Identifies Life-Threatening NSCLC Featuring Squamous and Glandular Biphenotypic Differentiation: Clinicopathologic Correlations;JTO Clinical and Research Reports;2021-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3